Trial Profile

A Phase I double-blind, placebo-controlled, single-ascending dose study of SBT-272 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevemipretide (Primary)
Indications Amyotrophic lateral sclerosis; Frontotemporal dementia; Multiple system atrophy; Parkinson's disease; Stroke
Focus Adverse reactions; First in man
Sponsors Stealth BioTherapeutics

Most Recent Events

01 Nov 2022 Interim results presented in a Stealth BioTherapeutics media release.
30 Mar 2022 According to a Stealth BioTherapeutics media release, first patent has been dosed in this trial.
21 Jan 2020 Status changed from planning to recruiting, according to a Stealth BioTherapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com